[go: up one dir, main page]

BE2015C031I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C031I2
BE2015C031I2 BE2015C031C BE2015C031C BE2015C031I2 BE 2015C031 I2 BE2015C031 I2 BE 2015C031I2 BE 2015C031 C BE2015C031 C BE 2015C031C BE 2015C031 C BE2015C031 C BE 2015C031C BE 2015C031 I2 BE2015C031 I2 BE 2015C031I2
Authority
BE
Belgium
Application number
BE2015C031C
Other languages
French (fr)
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of BE2015C031I2 publication Critical patent/BE2015C031I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/24—Preparation of ethers by reactions not forming ether-oxygen bonds by elimination of halogens, e.g. elimination of HCl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2015C031C 2003-12-16 2015-05-20 BE2015C031I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53012203P 2003-12-16 2003-12-16
US11/344,404 US20060182692A1 (en) 2003-12-16 2006-01-30 Chemically modified small molecules

Publications (1)

Publication Number Publication Date
BE2015C031I2 true BE2015C031I2 (en) 2024-08-08

Family

ID=46123946

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C031C BE2015C031I2 (en) 2003-12-16 2015-05-20

Country Status (2)

Country Link
US (7) US20060182692A1 (en)
BE (1) BE2015C031I2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
BRPI0718554A2 (en) * 2006-11-07 2013-11-19 Nektar Therapeutics Al Corp METHODS OF DOSAGE AND CO-ADMINISTRATION OF AN OPIOID AGONIST AND AN OPIOID ANTAGONIST
CN101631569B (en) * 2007-03-12 2012-11-14 尼克塔治疗公司 Oligomer-antihistamine conjugates
US8389759B2 (en) * 2007-03-12 2013-03-05 Nektar Therapeutics Oligomer-anticholinergic agent conjugates
EP2189460B1 (en) 2007-05-04 2014-04-23 Mallinckrodt LLC Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates
AU2008276385B2 (en) * 2007-07-17 2013-07-18 SpecGx LLC Preparation of N-alkylated opiates by reductive amination
KR20110004425A (en) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 Oral Administration of Peripheral Opioid Antagonists
MX347741B (en) * 2008-09-16 2017-05-10 Nektar Therapeutics Pegylated opioids with low potential for abuse.
US8269006B2 (en) * 2008-09-30 2012-09-18 Mallinckrodt Llc Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
JP5680069B2 (en) * 2009-06-11 2015-03-04 マリンクロッド エルエルシー Reductive amination of 6-ketonormorphinan by catalytic hydrogen transfer
ES2598496T3 (en) * 2009-06-11 2017-01-27 Mallinckrodt Llc Preparation of N-substituted 6-alpha-amino morphinans by catalytic hydrogen transfer
EP2621496B2 (en) 2010-09-30 2018-12-12 AstraZeneca AB Crystalline naloxol-peg conjugate
BR112013031420A2 (en) 2011-06-09 2016-08-16 Mallinckrodt Llc "process for preparing a 6-amino morphinan, composition comprising it and composition comprising an intermediate compound"
BR112014005421A2 (en) 2011-09-08 2017-04-04 Mallinckrodt Llc alkaloid production without the isolation of intermediates
EP3340972A4 (en) * 2015-09-18 2019-05-01 Oklahoma Medical Research Foundation METHOD FOR TRANSPORTING AN AGENT THROUGH THE HEMATO-ENCEPHALIC, HEMATO-COCHLEAR OR HEMATO-CEPHALORACHIDIAN BARRIER
GB201819985D0 (en) * 2018-12-07 2019-01-23 Csir Polymer-active ingredient conjugate
CN110903952B (en) * 2019-11-06 2023-05-26 天晴干细胞股份有限公司 A method for separating, purifying and resuscitating placental blood by using protection solution and placenta squeezer
US11181229B2 (en) * 2020-01-29 2021-11-23 Solid Industries, Llc Rigging ladder system for lighting fixtures or entertainment equipment
US20240288374A1 (en) 2023-02-13 2024-08-29 Zymeron Corporation Plasmonic nanoparticle platform for analyte detection

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837574A (en) * 1956-03-15 1958-06-03 Olin Mathieson Chlorination of alcohols
US4223163A (en) * 1976-12-10 1980-09-16 The Procter & Gamble Company Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3675588D1 (en) * 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JPH01207320A (en) 1988-02-15 1989-08-21 Daicel Chem Ind Ltd Production of aromatic polyether
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
DE69030829T2 (en) * 1989-03-10 1998-01-15 Hoffmann La Roche Drugs for the detection of drugs
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH0383914A (en) * 1989-08-18 1991-04-09 W R Grace & Co Drug carrier
DE3937797A1 (en) * 1989-11-14 1991-05-16 Basf Ag METHOD FOR PRODUCING POLYETHERGLYCOLES
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP2829794B2 (en) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 Orally administered pranoprofen formulation for sustained release
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
EP0689424B1 (en) 1993-03-17 1998-10-14 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5469478A (en) * 1994-07-15 1995-11-21 National Semiconductor Corporation Digital phase lock loop for jitter filtering and frequency offset compensation
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
EP0856026A1 (en) 1995-10-19 1998-08-05 Receptagen Corporation Discrete-length polyethylene glycols
US5639705A (en) * 1996-01-19 1997-06-17 Arco Chemical Technology, L.P. Double metal cyanide catalysts and methods for making them
ES2168610T3 (en) * 1996-03-12 2002-06-16 Alza Corp COMPOSITION AND GALENIC FORM CONTAINING AN OPIOID ANTAGONIST.
US5856369A (en) 1996-07-30 1999-01-05 Osi Specialties, Inc. Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts
DE19632440A1 (en) 1996-08-12 1998-02-19 Basf Ag Easily prepared and separated catalyst giving pure alkoxylation product with narrow molecular weight distribution
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
DE19651551C2 (en) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5972954A (en) * 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6163313A (en) 1997-12-12 2000-12-19 Aroyan; James L. Touch sensitive screen and method
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
ATE399809T1 (en) * 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp METHOD FOR PRODUCING POLYMER CONJUGATES
US6316644B1 (en) * 1998-03-30 2001-11-13 Lg Chemical Ltd. Pilyethoxylated retinamide derivatives and process for preparing the same
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR100345214B1 (en) 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
KR100702878B1 (en) * 1999-10-29 2007-04-04 넥타르 테라퓨틱스 Dry Powder Compositions With Improved Dispersibility
DE60026073T2 (en) * 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville STERRICOUS DERIVATIVES OF WATER-SOLUBLE POLYMERS
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
EP1642885B1 (en) * 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US20020182172A1 (en) * 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
WO2002051839A1 (en) * 2000-12-22 2002-07-04 Smithkline Beecham P.L.C. 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
DK1362053T3 (en) 2001-02-20 2008-03-10 Enzon Inc Terminally branched polymeric linkers and polymeric conjugates containing these
PE20020908A1 (en) * 2001-03-21 2002-10-26 Cell Therapeutics Inc RECOMBINANT PRODUCTION OF POLYANIONIC POLYMERS AND USE OF THE SAME
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) * 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CA2463580A1 (en) 2001-10-29 2003-05-08 Michael David Bentley Polymer conjugates of protein kinase c inhibitors
DE60219677T2 (en) 2001-10-30 2008-05-15 Nektar Therapeutics Al, Corp., Huntsville WATER-SOLUBLE POLYMER CONJUGATES OF RETINOIC ACID
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003285200A1 (en) 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
MXPA05009757A (en) 2003-03-13 2005-12-05 Controlled Chemicals Inc Compounds and methods for lowering the abuse potential and extending the duration of action of a drug.
US20050031549A1 (en) * 2003-06-09 2005-02-10 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
AU2004264818B2 (en) 2003-08-01 2011-09-29 Biocon, Ltd Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1694347B1 (en) 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
JP4991312B2 (en) 2003-12-16 2012-08-01 ネクター セラピューティクス Chemically modified small molecule compounds
EP2364735A3 (en) * 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
EP2010539B1 (en) 2006-04-21 2017-06-14 Nektar Therapeutics Stereoselective reduction of a morphinone
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof

Also Published As

Publication number Publication date
US8067431B2 (en) 2011-11-29
US20140303403A1 (en) 2014-10-09
US20150197470A9 (en) 2015-07-16
US20060182692A1 (en) 2006-08-17
US20170095565A1 (en) 2017-04-06
US20190099363A1 (en) 2019-04-04
US12016952B2 (en) 2024-06-25
US9388104B2 (en) 2016-07-12
US20120088745A1 (en) 2012-04-12
US20100210676A1 (en) 2010-08-19
US11129794B2 (en) 2021-09-28
US20210393513A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
NL300737I2 (en)
BE2014C003I2 (en)
BE2013C075I2 (en)
BE2013C069I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
JP2004002480A5 (en)
JP2004014094A5 (en)
BE2011C030I2 (en)
BE2013C034I2 (en)
BE2015C031I2 (en)
JP2003332696A5 (en)
JP2003279656A5 (en)
BE2012C053I2 (en)
JP2003267006A5 (en)
JP2004221992A5 (en)
JP2003338816A5 (en)
JP2004023790A5 (en)
JP2003318236A5 (en)
JP2004001482A5 (en)
JP2003266116A5 (en)
JP2004160152A5 (en)
JP2003283272A5 (en)
JP2004000676A5 (en)